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Abstract 
Introduction & Aim:  Much is known about alcoholic hepatitis (AH) that is severe enough to 
require hospitalization. The characteristics of individuals with alcoholic hepatitis presenting 
with mild to moderate severity are not well understood. In this study we investigated the risk 
factors, characteristics, and outcomes of mild to moderate AH.   
Methods:   Two hundred and fifty five Individuals with AH enrolled into a multicenter, 
prospective, observational study between 12/2014 and 4/2018 were included. Participants 
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were seen at enrollment, 6 months, and 12 months. Mild to moderate AH (M-AH) was 
defined as MELD  20 at presentation whereas severe AH as MELD ≥ 21.   
Results:  One hundred individuals had M-AH whereas 155 had severe AH. Individuals with 
M-AH were older (49 vs 44 years, p=0.01), had lower BMI (27 vs 31 kg/m2, p=0.0007) and 
more likely to be male (68% vs 55%, p=0.046) compared to severe AH group. A higher 
proportion in M-AH group consumed coffee in the last 5 years compared to the severe AH 
(29% vs 18%, p=0.03), and fewer had PNPLA3 risk allele G (p=0.019) compared to the 
severe AH group. Average drinks per drinking day (12.9 vs 10.7, p=0.13) and total number 
of drinks in last 30 day period (331 vs 280, p=0.14) were not different between two groups.  
Compared to severe AH, patients with M-AH had significantly lower mortality at 30 days (2% 
vs. 13.6%), 90 days (3% vs. 22.6%), and 12 months (10.4% vs. 31.4%) (p <0.001 for all).  
Conclusions:  Individuals with mild to moderate AH were older, less obese, drank coffee 
more often and carried more favorable PNPLA3 genotype compared to severe AH, despite 
similar alcohol consumption. Mild to moderate AH had substantial mortality with one in ten 
dying by 12 months.   
 
Key Words: Alcoholic hepatitis; PNPLA3; Coffee drinking; MELD    
 
Introduction 
Alcoholic liver disease (ALD) represents a clinical and histopathological spectrum ranging 
from simple steatosis, alcoholic steatohepatitis, and cirrhosis (Sozio and Crabb, 2008) 
Alcoholic hepatitis (AH), the most severe clinical manifestation of ALD among excessive 
drinkers, is characterized by sudden onset of jaundice and liver-related complications. It is 
associated with a high short term mortality ranging 15% to 35% within the first month after 
the diagnosis (Liangpunsakul, 2011; Maddrey et al., 1978; Orntoft et al., 2014) However, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
majority of these estimates have come from hospitalized patients with severe AH who are 
participating in clinical trials. There are many patients with less severe AH who are not 
hospitalized and their clinical characteristics and outcomes are not well understood.  
Model for End Stage Liver Disease (MELD) score, initially derived from a study to determine 
predictors of survival in a cohort of patients who underwent transjugular intrahepatic 
portosystemic shunt (TIPS), has been shown to be relevant in predicting 30- and 90-day 
mortality in patients with AH with similar sensitivity and specificity as Maddrey Discriminant 
function. (Dunn et al., 2005; Malinchoc et al., 2000) MELD score greater than 20 in AH 
patients is associated with a 90-day mortality rate of more than 20%. Therefore, patients with 
AH whose MELD > 21 are generally considered to have severe AH. (Dunn et al., 2005) 
(Dunn et al., 2005) Hence this serves as a good cut-off to categorize patients into those who 
present with severe and the rest who present with mild to moderate  AH. Knowing the 
characteristics of individuals who present with mild-moderate AH would be instructive in 
understanding risk factors for severe presentation.  
We have shown previously that PNPLA3 G allele among heavy drinkers was associated with 
alcoholic hepatitis. (Liangpunsakul et al., 2016) We also saw a lower prevalence of regular 
coffee consumption among heavy alcohol drinkers who develop AH. (Lianpunsakul, 2017) 
We wanted to determine the clinical features, environmental risk factors such as coffee 
consumption and genetic risk factors such as PNPLA3 of individuals with AH who present 
with mild to moderate AH (M-AH) compared to severe AH. In this study, we report the risk 
factors, clinical characteristics and outcomes of patients presenting with mild to moderate 
AH (M-AH) who are enrolled into a prospective study and followed for twelve months 
following their enrollment.  
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Methods 
The study consisted of individuals who were enrolled into TREAT 001 (NCT 02172898) 
study between 12/2014 and 04/2018. TREAT 001 was a multicenter, prospective, 
observational study of individuals with AH and heavy drinking controls.  The design of this 
study has been previously described in detail (Liangpunsakul et al., 2016), but in brief, 
individuals with AH and heavy drinking controls without liver disease meeting predefined 
eligibility criteria were enrolled at three large liver centers in the United States and were 
followed for 12 months.  This study was approved by the Institutional Review Boards at each 
of the participating centers and all participants signed an informed consent.   Individuals who 
are included in this analysis have been part of several other publications by our group.  
Demographic data, past medical history, clinical characteristics, questionnaires and blood 
samples were collected at the time of enrollment. Alcohol Use Disorders Identification Test 
(AUDIT) and the Time Line Follow-Back (TLFB) were used to characterize the alcohol 
consumption data. Coffee questionnaire captured duration and quantity per day of coffee 
and tea consumption. PNPLA3 genotype was determined according to methods previously 
described.  The study protocol included an enrollment visit and visits at 6 and 12 months.  
Death was ascertained by direct family contact and in case of individuals who were lost to 
follow up it was through the National Death Registry.  All subjects with a MELD score ≤ 20 at 
presentation were defined as having mild to moderate AH (M-AH) and those with MELD ≥ 21 
was defined as severe AH.  
 
Statistical analysis  
Pearson’s chi-square test and two-sample t-tests were employed to determine the 
differences of the categorical and continuous variables, respectively, between patients with 
moderate and severe AH.  When sample sizes were small, Fisher’s exact test was applied 
instead of Pearson’s chi-square test. Survival analysis between patients with moderate and 
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severe AH was estimated using the Kaplan-Meier method, and the differences were 
compared using the log-rank test. A p-value <0.05 was considered statistically significant.  
 
Results  
During the study period, 255 individuals with AH were enrolled, of whom 100 had M-AH and 
155 had severe AH.  Baseline demographics and selected clinical characteristics of two 
groups are shown in Table 1.  Among individuals with M-AH, the MELD score was between 
11 and 20 in 93, 10 in 3, and 9 in 4 participants.  Individuals with M-AH were older (49 vs 44 
years, p=0.01) and were more likely to be male (68% vs 55%, p=0.046) when compared to 
those with severe AH.  They also had a significantly lower BMI compared to those with 
severe AH (27 vs 31 kg/m2, p < 0.05). Although patients with M-AH had higher levels of ALT 
(82 vs 48 U/L, p<0.0001) and AST (163 vs 126 U/L, p=0.001), they demonstrated less 
severe liver synthetic dysfunction, as reflected in higher serum albumin (3.0 vs 2.7 gm/dL, p 
< 0.05), lower total bilirubin (6 vs 15 mg/dL, p < 0.0001) and lower international normalized 
ratio (1.4 vs 2.1, p < 0.0001).  
A higher proportion of individuals with M-AH were coffee drinkers in last five years compared 
to those with severe AH (29% vs 18%, p=0.03. (Table 2) There was no significant difference 
in average drinks per drinking day (12.9 vs 10.7, p=0.13) or total number of drinks in the last 
30 days (331 vs 280, p=0.14) between two groups. (Table 2)  
Fewer individuals with M-AH AH carried the PNPLA3 genotypes with high risk G allele (GG 
and GC) compared to those with severe AH. The frequency of PNPLA3 CC, CG, and GG 
genotypes in M-AH were 55%, 38%, and 7% respectively and it was significantly different 
from severe AH group (CC: 34%, CG: 52%, and GG: 13%, p=0.02).  
There was a significant interaction between coffee drinking and the PNPLA3 genotype 
(p=0.0037). (Table 3) Among those carrying high risk PNPLA3 G allele, fewer proportion of 
coffee consumers presented with severe AH compared to non-consumers of coffee. (52.2% 
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vs 74% respectively) Even among those with favorable PNPLA3 genotype profile (CC), 
fewer proportion of coffee consumers presented with severe AH compared to non-
consumers of coffee. (33.3% vs 53.6%) (Table 3).  
Compared to individuals with severe AH, patients with M-AH had significantly lower mortality 
at 30 days (2% vs. 13.6%, p<0.001), 90 days (3% vs. 22.6%, p<0.001), and 12 months 
(10.4% vs. 31.4%, p<0.001) (p <0.001 by Log-rank test). (Figure 1) The causes of death for 
individuals with M-AH were complications of end stage liver disease in 5, unknown causes in 
2, complications from accidental falls in 2, clostridium difficile colitis in 1.  
 
Discussion    
Our study shows that a substantial proportion of AH patients (40%) seeking medical 
attention have mild to moderate AH, as defined by a MELD score   20. A majority of them 
with M-AH had MELD scores between 11 and 20 with a small minority presenting with MELD 
less than 11.  Individuals with M-AH in our study were found to have lower BMI and fewer 
females compared to those with severe AH.  While excess body weight and female sex were 
previously shown to be associated with an increased risk for AH (Liangpunsakul et al., 
2016), our study is the first to observe that female sex and overweight are associated with 
severity of AH as well.  
Lack of significant relationship between amount of alcohol consumed or duration of alcohol 
consumption by heavy drinkers and the disease severity is interesting. These results are 
consistent with our previous  observation that the degree of alcohol consumption was not 
associated with the risk for AH among heavy drinkers.(Liangpunsakul et al., 2016) This 
suggests that once the level and duration of alcohol consumption reach a threshold it is the 
demographic, genetic, and environmental factors, which determine the risk for developing 
AH as well as its severity at presentation.  
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In addition to the demographic differences, we observed significant differences in 
environmental risk factors. Higher proportion of individuals with M-AH consumed coffee in 
the last five years compared to those with severe AH.  This very interesting finding 
corroborates previous observations of coffee consumption as a protective risk modifier in 
development of hepatic fibrosis after adjusting for age, sex, BMI and liver disease diagnosis 
and alcohol intake. (Liu et al., 2015; Molloy et al., 2012)  
We and others have previously shown that PNPLA3 G allele is associated with alcoholic 
cirrhosis and alcoholic hepatitis. (10, 11) Our data suggests that PNPLA3 G allele may also 
be associated with severity of AH. We have previously shown an interaction between 
PNPLA3 genotype and coffee drinking and the risk for AH among heavy drinkers. 
(Liangpunsakul, 2017)  The current study suggests a similar interaction between coffee 
drinking and PNPLA3 genotype in modifying the AH severity.  Coffee consumption in high 
risk PNPLA3 allele carriers, reduced the proportion of individuals presenting with severe AH 
to that seen in low risk PNPLA3 allele carriers who were not coffee consumers. Coffee 
consumption among the low risk PNPLA3 allele carriers, drove this proportion further down. 
Although individuals with moderate AH fared better than those with severe AH, their mortality 
was still substantial with one year mortality of 10.4%. Another important observation is that a 
half of deceased individuals with mild to moderate AH died from reasons other than liver 
failure such as accidental falls (in 20%), infection (10%) and unknown (20%).  Different 
strategies will likely be needed to prevent these non-hepatic causes of death in this patient 
population.  
In summary, our data shows that in a population of AH patients, close to 40% present with 
M-AH. These patients are older, less likely to be female and have lower BMI compared to 
patients presenting with severe AH. Although their level of alcohol consumption was similar, 
patients with M-AH more commonly report coffee consumption and have lower frequency of 
carrying high risk PNPLA3 G allele compared to severe AH, suggesting the role of genetic 
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and environmental factors in modifying disease severity. Their mortality is substantial with 1-
year mortality of 10.4%, with half of deaths due to non-liver related causes.      
 
Table 1:  Selected Demographic and Laboratory Characteristics of Individuals   
With Mild to Moderate and Severe AH¶ 
 
 
Mild to 
Moderate AH 
(n=100) 
Severe AH 
(n=155) 
P-value 
   Age (years) 
 
49.0 ± 10.4 
 
44.5 ± 10.9 
 
0.001 
 
   Male (%) 68  55.5 0.046 
   White (%) 83  89 0.16 
   PTSD (%) 37 32 0.55 
BMI (Kg/m2) 27.5 ± 6.0 30.8 ± 8.2 0.0007 
WBC (x 103/mm3) 8.4 ± 5.4 13.5 ± 8.4 <.0001 
Hemoglobin (gm/dl) 10.3 ± 2.0 10.0 ± 2.0 0.17 
Platelet (x 103/mm3) 131.9 ± 82.5 147.2 ± 83.1 0.15 
Total Bilirubin 
(mg/dl) 
5.7 ± 4.4 19.5 ± 10.9 <.0001 
INR 1.4 ± 0.3 2.1 ± 0.6 <.0001 
AST (U/L) 162.9 ± 110.5 126.5 ± 65.6 0.0011 
ALT (U/L) 81.8 ± 82.5 48.3 ± 35.8 <.0001 
Albumin (g/dl) 3.0 ± 0.8 2.7 ± 0.6 0.009 
Creatinine (mg/dl) 0.7 ± 0.2 1.3 ± 1.4 <.0001 
MELD score 16.1 ± 3.1 27.2 ± 5.8 <.0001 
 
¶Values are shown as means ± standard deviation unless otherwise specified 
Abbreviations; BMI: Body Mass Iindex; WBC: White Blood Cells; INR; International 
Normalized Ratio; MELD score: Model for End Stage Liver Disease.   
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Table 2: Coffee and Alcohol Consumption of Individuals with Mild to Moderate  
and Severe AH¶ 
 
 Mild to 
Moderate AH 
(n=100) 
Severe AH 
(n=155) 
P-value 
Years of alcohol 
drinking  
25.6 ± 14.5 25.1 ± 10.6 0.87 
Average alcohol Drinks 
per Drinking Day 
12.9 ± 11.8 10.7 ± 8.0 0.13 
Alcohol drinks per last 
30 day period 
331.5 ± 273.3 280.1 ± 209.6 0.15 
Average alcohol 
consumed per drinking 
day (Grams) 
193.2 ± 177.0 160.5 ± 119.9 0.135 
Coffee drinking (%) 29 18 0.035 
Years of drinking 
coffee? (if ≥ 5 years)  
25.6 ± 14.5 25.1 ± 10.6 0.8748 
Cups of caffeinated 
coffee per day (if ≥ 5 
years) 
4.6 ± 8.1 2.3 ± 1.9 0.1439 
   
 ¶ Values are shown as means ± standard deviation unless otherwise specified 
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TABLE 3:  The relationship between PNPLA3 genotypes and coffee consumption and  
the severity of AH (N=174) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Mild to moderate 
AH 
(n=69) 
Severe AH 
(n=105) 
P-value  
PNPLA3 CC genotype + Coffee drinking 12 (66.7%) 6 (33.3%) 0.0037 
PNPLA3 CC genotype + No coffee 
drinking 
26 (46.4%) 30 (53.6%) 
PNPLA3GG/GC genotype + Coffee 
drinking 
11 (47.8%) 12 (52.2%) 
PNPLA3GG/GC genotype + No coffee 
drinking 
20 (26.0%) 57 (74.0%) 
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Figure Legend  
 
Figure 1 
Kaplan-Meier survival curves of Individuals with Mild to Moderate and Severe Alcoholic 
Hepatitis.  The number of participants available at each time point is shown under the X-axis.  
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